Alemtuzumab News and Research

RSS
Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genzyme, Sanofi-Aventis enter confidentiality agreement

Genzyme, Sanofi-Aventis enter confidentiality agreement

Genzyme provides update on discussions with Sanofi-Aventis

Genzyme provides update on discussions with Sanofi-Aventis

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genmab A/S reports DKK 78 million in net sales for Arzerra

Genmab A/S reports DKK 78 million in net sales for Arzerra

Genzyme third quarter revenue increases to $1.0 billion

Genzyme third quarter revenue increases to $1.0 billion

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme reports five-year patient data from Phase 2 multiple sclerosis trial

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Sanofi-aventis commences tender offer for Genzyme acquisition

Sanofi-aventis commences tender offer for Genzyme acquisition

British, Austrian scientists awarded K. J. Zülch Prize for basic neurological research

British, Austrian scientists awarded K. J. Zülch Prize for basic neurological research

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

Genzyme responds to Sanofi-Aventis' unsolicited acquisition proposal

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme second-quarter revenue decreases to $1.08 billion

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

Genmab reports Arzerra net sales of DKK 73 million during second-quarter 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genzyme to initiate $2 billion stock buyback

Genzyme to initiate $2 billion stock buyback

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme announces fourth-quarter and full-year 2009 financial results